Factors Affecting Mortality and Complications in Mushroom Poisonings Over a 20 Year Period: A Report from Central Anatolia  by CEVIK, Arif Alper & UNLUOGLU, Ilhami
Turk J Emerg Med 2014;14(3):104-110      doi: 10.5505/1304.7361.2014.36024
Submitted: March 16, 2014    Accepted: April 22, 2014    Published online: Agusut 30, 2014
Correspondence: Arif Alper Cevik, MD, FEMAT.  United Arab Emirates University, College of Medicine and Health Sciences, Al Ain, UAE.
e-mail: aacevik@uaeu.ac.ae
ORIGINAL ARTICLE
1Department of Emergency Medicine, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir
2United Arab Emirates University, College of Medicine and Health Sciences, Al Ain, UAE
3Department of Family Medicine, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir
Arif Alper CEVIK,1,2 Ilhami UNLUOGLU3
Factors Affecting Mortality and Complications
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A Report from Central Anatolia
Yirmi Yılda Mantar Zehirlenmelerinde Mortalite ve
Komplikasyonu Etkileyen Faktörler: Anadolu’dan Bir Rapor
SUMMARY
Objectives
Mushroom poisoning (MP) is one of the world’s leading seasonal and re-
gional health problems. The aim of this study was to analyze the relation-
ship between clinical factors and outcomes of mushroom poisoning.
Methods
The study was conducted in the emergency department. The patients 
who presented between January 1st, 1991 and December 31, 2010 
were retrospectively reviewed. 
Results
599 MP cases were enrolled into the statistical analysis. The elderly 
group had a higher rate of mortality (8.8%) and complications (12.3%) 
(p=0.005) (OR 3.98, 95% CI: 1.9291 to 8.2290; p=0.0002). The patients 
who presented in summer had a higher rate of mortality (9.5%) and 
complications (11.9%) (p<0.001). (OR: 3.83, 95% CI 1.7068 to 8.6074, 
p=0.0011). The rate of mortality and complications in patients who 
had eaten self-harvested wild mushrooms (WM) was 6.8%, while those 
who purchased WM had a mortality and complication rate of 15.2% 
(p=0.016), (Purchased WM OR 2.46, 95% CI 1.1609 to 5.2353, p=0.0189). 
The rate of mortality and complications in the patients who presented 
with gastrointestinal symptoms was 9.9% (OR: 3.98, 95% CI 1.5503 to 
10.2679; p=0.0041).
Conclusions
Factors such as being elderly, summer season, purchased WM, and 
gastrointestinal symptoms were significantly associated with mortality 
and complications in our study.
Key words: Elderly; emergency department; mushroom; poisoning; sum-
mer season.
ÖZET
Amaç
Mantar zehirlenmeleri (MZ) dünyanın önde gelen mevsimsel ve bölgesel 
sağlık problemidir. Bu araştırmanın amacı MZ’de klinik faktörlerle sonuçlar 
arasındaki ilişkiyi incelemektir.
Gereç ve Yöntem
Araştırma Acil Tıp departmanında gerçekleştirilmiştir. 1 Ocak 1991 ve 31 
Aralık 2010 tarihlerinde başvuran hastalar geriye dönük olarak incelen-
miştir.
Bulgular
599 MZ olgusu araştırmaya dahil edildi. Yaşlı hastalar daha yüksek mor-
talite (%8.8) ve komplikasyon (%12.3) oranına sahiptiler (p=0.005). (Odd 
oranı [OO]: 3.98, %95 [Güven Aralığı] GA 1.9291 - 8.2290, p=0.0002). Yaz 
aylarında başvuran hastalar daha yüksek mortalite (%9.5) ve komplikas-
yona (%11.9) sahiptiler (OO: 3.83, %95 GA 1.7068 to 8.6074, p=0.0011). 
Mantarları kendi toplayıp yemiş olan hastalarda mortalite ve komplikas-
yon oranı %6.8 iken bu oran satın alınmış vahşi mantarlarda %15.2 idi 
(p=0.016), (satın alınan mantarlar için OO: 2.46, 95% GA 1.1609 - 5.2353, 
p=0.0189). Gastrointestinal semptomları olan hastaların mortalite ve 
komplikasyon oranı %9.9 olarak saptandı (OO: 3.98, %95 GA 1.5503 - 
10.2679, p=0.0041). 
Sonuç
Yaşlılık, yaz mevsimi, satın alınmış vahşi mantarlar ve gastrointestinal 
semptomlar mortalite ve komplikasyonlar ile anlamlı ilişki göstermiştir.
Anahtar sözcükler: Yaşlılık; acil servis; mantar; zehirlenme; yaz mevsimi.
104
© 201  Emergency Medicine Association of Turkey. Production and Hosting by Elsevier B.V. Originally published in [201 ] by 
Kare Publishing. This is an open access article under CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
44
Introduction
Mushroom poisoning (MP) is one of the world’s leading sea-
sonal and regional health problems. Eating poisonous wild 
mushrooms (WM) can lead to unwanted reactions such as 
gastroenteritis or more severe pathologies including fatal 
liver failure. Fatal MP is very well described in the literature.
[1] Fortunately, though, the majority of MP cases have a good 
prognosis.
The Central Anatolian region of Turkey has considerable 
reputation in terms of MP. MP can be commonly observed in 
Europe, Anatolia and the Middle East, and the reports from 
these regions, including incidence and prognosis, have sig-
nificant differences.[2-5] 
In our previous studies, we tried to call attention to differ-
ent aspects of MP.[6-8] These studies consisted of short-term 
data and had no detailed evaluation of the relationship be-
tween clinical data and outcome measures (mortality and/or 
complications). As far as we are aware, in the English litera-
ture, the number of studies evaluating this relationship and 
prognostic criteria is limited. Additionally, other studies have 
concentrated on different variables.[9-11] 
The aim of our study was to analyze the relationship be-
tween clinical factors and outcomes of MP. In this study, we 
report MP cases admitted to our hospital serving four Anato-
lian cities with a total population of approximately two and a 
half million people over the last 20 years.
Materials and Methods 
Hospital
The study was conducted in the emergency department of 
the university hospital, which is a tertiary care center for all 
medical and trauma patients, as well as for toxicology and 
environmental cases. 
Patients
The patients who presented or transferred to the emergency 
department and were diagnosed as MP between January 
1st, 1991 and December 31, 2010 were included in the study 
group. The patients included into the study group were se-
lected according to the inclusion criteria.
Data acquisition
ICD-10 and 9 codes of MP were entered into the hospital in-
formation system. The list of cases was obtained by use of 
these codes. The detailed information of cases was found 
retrospectively in electronic health records as well as in ar-
chived patient files for cases admitted before 2007.
Basic descriptive data of cases including age (age groups [0-
17: child and adolescent, 18-39: young adults, 40-64: mid-
dle age, 65 and older: elderly), gender, presenting months 
and seasons, presenting symptoms (neurological, gastro-
intestinal, and other), how WM were obtained (self harvest 
from nature, purchased from public market), the means of 
admission (direct presentation or transferred), laboratory 
results (Blood Urea Nitrogen (BUN, mg/dL), Creatinine (Cr, 
mg/dL), alanine aminotranferase (ALT, U/L), aspartate ami-
notransferase (AST, U/L), clinical care area (emergency de-
partment, ward, or intensive care unit [ICU]), length of stay 
in the hospital, and outcome (mortality, complication (end 
stage renal failure, seizure disorder, etc.), full recovery) were 
collected. 
Inclusion and Exclusion Criteria
The patients who had the above clinical/laboratory details 
in their files were included into the study. The patients who 
had co-ingestion of drugs in overdose, drugs of abuse, miss-
ing clinical follow-up or did not have the above clinical/labo-
ratory details in their files were excluded from the study.
Outcome Measures
Patient data were evaluated for their relationships with mor-
tality, complications (end stage renal failure, seizure disor-
der, etc.), and full recovery.
Data Analysis
Statistical Package for the Social Sciences (SPSS, version 18) 
and Statistical Analysis and Graphics Software (NCSS 2007) 
were used for statistical analyses. Chi-Square and the Fisher 
Exact test were used for descriptive analyses. Kolmogorov-
Smirnov test was used to show the distribution of the data. 
Mann-Whitney U-test in binary groups and Kruskal-Wallis 
One Way Analyses of Variance test for three or more groups 
of data were used, as the data did not show a normal distri-
bution in the Kolmogorov-Smirnov test. Median values were 
given for the results of variables that did not show normal 
distribution. Odds ratio (OR) was calculated for variables that 
may affect the outcome, such as age, presenting symptoms, 
the way of obtaining WM, and admission. A p-value less than 
0.05 was accepted as significant. SD: standard deviation, SE: 
standard error.
Results
721 MP cases were admitted to the hospital within a period 
of 20 years. 117 cases who did not have clinical/laboratory 
information in their files and five patients who had been 
transferred to different cities were removed from the study. 
599 cases were enrolled into the statistical analyses.
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Gender and Age Groups
There were 319 females (53.3%) and 280 males in the study. 
The mean age of males and females were similar. According 
to age groups, there were 162 (27.0%) cases in children and 
adolescents, 187 (31.2%) cases in young adults, 193 (32.2%) 
cases were in middle-aged adults, and 57 (9.5%) in the el-
derly. Comparison data on gender and age groups are pre-
sented in Table 1. Although distributions of genders were 
similar in three age groups, the number of female patients in 
the young adult group was significantly higher (120, 64.2%) 
(χ2=13.56, p=0.004). 
There were no significant differences between genders and 
among the age groups for patients’ presenting season, the 
means of obtaining WM, and symptoms. There were no dif-
ferences between genders for distribution of clinical care 
area and outcome. However, there was a significant differ-
ence among the age groups for distribution in the clini-
cal care area. The child and adolescent group was mainly 
treated in the ward area (128 cases, 79.0%) while 43 cases 
(75.4%) from the elderly group received medical care in the 
ICU (χ2=325,932, p<0.001). The elderly group had a higher 
rate of mortality (8.8%) and complications (12.3%) than the 
other age groups (χ2=18.664, p=0.005). The odds ratio (OR) 
was 3.98 (95% CI: 1.9291 to 8.2290, Z = 3.736, p=0.0002). 
The mean ages of the patients in mortality, complication 
and full recovery groups were significantly different (41.50 
[SE: 4.45], 44.91 [SE: 4.26], 33.98 [SE: 0.88] respectively, 
χ2=6.429904, p=0.0401).
Presenting Season
The seasonal distribution of MP showed a binary peak. 
Spring (April, May, June) had the highest number of patients 
(367 cases, 61.3%). Autumn (October, November, December) 
was the second highest season with 166 cases (27.7%). The 
highest number of patients was seen in June (237, 39.5%).
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Table 1. Comparison data on gender and age groups
 Gender Age Group (years)
 Female Male 0-17 18-39 40-64 ≥65
  n % n % n % n % n % n %
N  319 53.3 280 46.7 162 27 187 31.2 193 32.2 57 9.5
Mean age (SD) 32.25 (19.85) 35.19 (22.26) 9.29 (4.31) 28.63 (6.28) 50.76 (6.70) 72.79 (4.71)
Presenting season
 Winter 12 3.8 12 4.3 4 2.5 9 4.8 8 4.1 3 5.3
 Spring 198 62.1 169 60.4 96 59.3 123 65.8 113 58.5 35 61.4
 Summer 20 6.3 22 7.9 11 6.8 13 7.0 13 6.7 5 8.8
 Autumn 89 27.9 77 27.5 51 31.5 42 22.5 59 30.6 14 24.6
Obtaining WM
 Self harvest 281 88.1 252 90 149 92.0 167 89.3 170 88.1 47 82.5
 Purchased from public market 38 11.9 28 10 13 8.0 20 10.7 23 11.9 10 17.5
Presenting symptoms
 Neurologic 72 22.6 61 21.8 32 19.8 41 21.9 50 25.9 10 17.5
 Gastrointestinal 221 69.3 192 68.6 124 76.5 124 66.3 122 63.2 43 75.4
 Other 26 8.2 27 9.6 6 3.7 22 11.8 21 10.9 4 7.0
Clinical care area
 Emergency department 70 21.9 53 18.9 11 6.8 50 26.7 50 25.9 12 21.1
 Ward 73 22.9 83 29.6 128 79.0 16 8.6 10 5.2 2 3.5
 ICU 176 55.2 144 51.4 23 14.2 121 64.7 133 68.9 43 75.4
Outcome
 Full recovery 295 92.5 258 92.1 151 93.2 179 95.7 178 92.2 45 78.9
 Mortality 11 3.4 11 3.9 6 6.3 3 1.6 8 4.1 5 8.8
 Complications* 13 4.1 11 3.9 5 3.1 5 2.7 7 3.6 7 12.3
*End stage renal failure in 23 patients and permanent seizure in one patient were complications in our study.
Neurologic symptoms were higher in autumn (109 of 133 
cases, 82.0%). Gastrointestinal symptoms were common in 
spring (218 of 413 cases, 52.8%) and autumn (143 of 413 
cases, 34.6%). Presenting symptoms differed significantly 
among seasons (χ2=43.578, p<0.001).
In winter, complications were seen in only two cases, while 
there were no fatal cases. The patients who presented in 
summer had a higher rate of mortality (9.5%) and complica-
tions (11.9%) than other seasons (χ2=28.108, p<0.001). The 
OR was found to be 3.83 (95% CI: 1.7068 to 8.6074, Z=3.255, 
p=0.0011).
The means of obtaining mushrooms
The majority of cases (foragers) had obtained and eaten self-
harvested WM (533 cases, 89.0%), while 66 patients (11.0%) 
had eaten WM purchased from a public market.
282 patients who had eaten self-harvested WM were treat-
ed in the ICU (52.9%). The ICU admission rate was higher in 
patients (38 cases, 57.6%) who had eaten purchased WM 
(χ2=7.084, p=0.029).
The outcome was also significantly different between these 
two groups. The rate of mortality and complications in the 
patients who had eaten self-harvested WM was 6.8% (36 
of 533 cases, 19 mortality, 17 complications), while the 
group that purchased WM had a 15.2% rate of mortality and 
complications (10 of 66 cases, 3 mortality, 7 complications 
(χ2=5.841, p=0.016). The OR of purchased WM was found to 
be 2.46 (95% CI: 1.1609 to 5.2353, Z=2.348, p=0.0189).
Presenting symptoms
Patients described gastrointestinal (413 cases, 68.9%), neu-
rologic (133 cases, 22.2%) or other symptoms (53 cases, 
8.8%) as their first presenting symptom. Among all symp-
toms, nausea was the most common (322 cases, 53.8%), fol-
lowed by light-headedness and vomiting (13.4% and 8.3%, 
respectively).
The rate of mortality and complications in the patients who 
presented with gastrointestinal symptoms was 9.9% (41 of 
413 cases, 20 mortality, 21 complications). The OR of gas-
trointestinal symptoms for mortality and complications was 
3.98 (95% CI: 1.5503 to 10.2679, Z=2.869, p=0.0041). The rate 
of mortality and complications was lower in patients with 
neurological symptoms (3.0%) and the other symptoms 
(1.9%). There was a significant difference for mortality and 
complications among the groups (χ2=9.547, p=0.008).
Admission to the hospital and length of stay
121 (20.2%) patients directly presented to our emergency 
department. The majority of cases had first been admitted to 
primary or secondary health care centers (478 cases, 79.8%), 
and then were transferred to our emergency department. 
Forty-seven of the 121 (38.8%) directly presented cases were 
admitted to the ICU, while the ICU admission rate was 57.1% 
in transferred cases (χ2=16.620, p<0.001).
The patients who were admitted had clinical care in three 
different locations: 320 cases (53.4%) in the ICU, 156 cases 
(26.0%) in the ward, and 123 cases (20.5%) in the emergency 
department.
The hospital length of stay of transferred cases (mean: 3.24 
(CI: 2.86-3.61); median: 2.0) was significantly higher than in 
the directly presented group (mean: 2.42 (CI: 2.02-2.83); me-
dian: 2.0) (p<0.001).
The elderly group had 5.80 (SE: 0.50) days of hospital stay. 
Child and adolescent, young adult, and middle age groups 
had 2.90 (SE: 0.29), 2.51 (SE: 0.27), and 2.95 (SE: 0.27) days, re-
spectively. There was a significant difference among the age 
groups for length of hospital stay (χ2=18.36774, p<0.001). 
The mean length of stay of fully recovered patients was 2.76 
(SE: 0.15) days, while the mean lengths of stay were 7.31 (SE: 
0.79) days in fatal cases and 6.37 (SE: 0.76) days in compli-
cated cases (χ2=5.908688, p=0.043).
Mortality and complications in directly presented cases were 
0.8% (one case) and 3.3% (four cases) respectively. Trans-
ferred cases had higher rates of mortality (21 cases, 4.4%) and 
complications (20 cases, 4.2%). Although there was a differ-
ence between the two groups, it was not significant. The OR 
for transferred cases was found to be 2.17, but it was also not 
significant (95% CI: 0.8412 to 5.6324, Z=1.603, p=0.1088).
Laboratory Results
BUN, Cr, AST and ALT levels of all cases were evaluated. All 
laboratory levels showed differences between outcome 
groups. The levels evaluated were the first laboratory levels 
obtained in the emergency department.
Mean BUN levels by outcome were found as follows: 16.14 
(SE: 0.58) in the full-recovery group, 35.09 (SE: 2.93) in the 
mortality group, and 61.54 (SE: 2.80) in the complication 
group (χ2=59.43019, p<0.001). Creatinine levels were 1.10 
(SE: 8.20) in the full-recovery group, 3.19 (SE: 0.41) in the 
mortality group, and 4.27 (SE: 0.39) in the complication 
group (χ2=58.21726, p<0.001). AST levels were 63.79 (SE: 
28.66) in the full-recovery group, 2983.09 (SE: 143.73) in the 
mortality group, and 313.58 (SE: 137.61) in the complication 
group (χ2=83.94112, p<0.001). ALT levels were 62.83 (SE: 
31.01) in the full-recovery group, 3056.95 (SE: 155.48) in the 
mortality group, and 480.20 (SE: 148.86) in the complication 
group (χ2=74.45051, p<0.001).
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Discussion
Most articles on MP are case reports or series. The effects of 
demographic data and other key information on outcomes 
are not well studied or published in the literature. There are 
many factors that affect the outcome of MP, including type 
of ingested mushroom, location, the amount of toxin deliv-
ered, laboratory results, clinical findings, medical treatment 
given, hemodialysis, or liver transplantation. In addition to 
many known details of this toxicity, MP still has some diag-
nostic and treatment dilemmas for medical professionals.
Although MP has a complex and challenging clinical prog-
ress, mortality is seen very rarely. In 2010, 6,275 MP cases 
were reported to the American Association of Poison Con-
trol Centers (AAPCC). Only one death was reported.[12] Un-
fortunately, there is no center collecting poisoning reports 
in Europe and in the Middle East. There are also no annually 
published poisoning reports in these regions. Therefore, it 
is difficult to estimate the true incidence of MP in this part 
of the world. According to the report of one of the regional 
poison information centers in our country, MP accounted 
for 1.2% (799 cases) of the 65,176 poisoning cases in the 
last 14 years. Only one death was reported in this report, 
and the source was an unknown type of WM4. Although 
public awareness about WM and a more skeptical approach 
by physicians to MP has decreased mortality, some unpub-
lished reports of deaths have been declared to be fatal MP 
cases in the Assam area of India in 2008.[13]
There are different reasons for exposure to WM in different 
age groups. Children may be unintentionally poisoned by 
eating WM found in outdoor areas.[2] However, adults are 
more prone to collect and eat WM intentionally. Schenk-Jae-
ger et al. reported that 86.4% of their cases were accidental 
exposure to mushrooms.[2] They also report abuse and sui-
cide cases (12.8% and 6.3%, respectively). We did not de-
termine abuse or suicidal ingestion in our cases. Hocaoglu’s 
study also had the same finding.[4]
The number of female patients was found to be higher in 
our study as in some other reported studies.[3,4,14] Hocaoglu 
reported a female/male ratio of 1.24. Another report from 
northeast part of Turkey found 67.5% female patients.[3] In 
the present study, we have no strong data showing a rela-
tionship between gender and outcome.
We can estimate risk groups for poisoning because of their 
physiologic and metabolic factors or comorbidities. Children 
and elderly are at the greatest risk for toxicity and the worst 
outcomes for all types of poisoning. Therefore, evaluation of 
the outcome among the age groups was one of the main 
focuses of our study. In 2010, AAPCC reported that 70.1% of 
all MP cases were in patients with an age of 19 years or less.
[12] Although our study did not use the same age ranges as 
the AAPCC report, we found 27.0% of cases in those patients 
less than 18 years old. This demonstrated a difference in the 
age distribution of MP cases between countries. Mortality 
and complication rate (21.3%) in the elderly group (65 and 
older) in our study was higher than the other age groups, 
with an OR of 3.98. In patients under 19 years old, we found 
a 9.4% rate of mortality and complications. The mean age 
of full-recovery cases was also significantly lower than the 
mortality and complication groups. According to this find-
ing, we may suggest that MP does not have the worst out-
comes in children and adolescents. However, mortality and 
complication rates rise with increasing age according to our 
results and our previous report.[8] Because our study showed 
that elderly patients have the worst outcomes, emergency 
physicians and ICU physicians should pay special attention 
in taking care of this age group.
MP has some seasonal variations in literature. Schenk-Jaeger 
et al. reported that there is one peak in their study, occur-
ring in late summer.[2] In Ishihara’s report, summer and early 
autumn were the most common seasons for MP.[15] MP in our 
region has a binary peak, in spring and autumn. However, 
mortality and complication rates were highest in summer 
(total 21.4%). Most WM poisoning affects the gastrointesti-
nal system, and patients present with nausea, vomiting or 
diarrhea. The most serious effect of MP is on the kidneys 
and liver. Deterioration of these two important organ func-
tions and failure to recover lead to mortality or irreversible 
complications such as permanent renal failure. Dehydration 
is one of the main problems, and it worsens renal function. 
Inadequate supportive treatment may lead to renal failure. 
This may affect the outcome, especially in elderly patients. 
Cases of acute prerenal failure following dehydration are ob-
served not only in elderly patients, but also in young and 
previously healthy patients.[2]
Eating WM in our country is still a quite common habit. WMs 
are also commonly sold in public markets, and there are no 
regional or national regulations to control it. Yardan et al. 
showed that 87.7% of patients had collected and ate WM, 
while only 12.3% had purchased WM from a local bazaar.[3] 
These findings are quite similar to our results. Foragers usu-
ally pick WM from open rural fields, woodlands, gardens, or 
roadsides, then cook and eat.[7] This habit is also widespread 
in European and Middle Eastern countries.[2,5] Unfortunately, 
we found higher mortality and complications in patients 
who purchased WM from public markets. This is one of the 
main issues of public health in many countries. Emergency 
physicians may play a more active role in educating the pub-
lic on MP.
MP may present varying grades of gastrointestinal and 
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neurologic symptoms and hepatic/renal involvement de-
pending on the type and amount of mushroom consumed. 
Gastrointestinal symptoms were the most prominent com-
plaints in our patients. We found that gastrointestinal symp-
toms have higher mortality and complication rates. Most 
reports indicate that gastrointestinal symptoms, especially 
nausea, vomiting and diarrhea, are prominent symptoms. 
Nausea and vomiting were found in 86.8% and 79.8% of 
cases in the middle Black Sea region of Turkey.[3] Nausea and 
vomiting were determined in 93.8% of cases in another re-
port.[16]
A. phalloides is one of the well-known toxic mushrooms 
which cause these symptoms. It is also considered the sole 
cause of liver damage.[17] Differentiating benign gastroen-
teritis from potentially life-threatening A. phalloides (ama-
toxin) poisoning is critical for health care professionals. A. 
phalloides causes these symptoms, as do other types of 
mushrooms, and inadequate treatment or delayed diagno-
sis can increase the chance of mortality and complications. 
In the literature, A. phalloides toxicity is responsible for 90% 
of fatal MP.[18,19] Liver failure because of toxic mushrooms may 
be fatal if the organ transplantation cannot be arranged.[19] 
We have Amanita, Gyromitra, Inocybe and Omphalatus spe-
cies in our region.[8] The majority of deaths are thought to be 
due to Amanita. However, diagnostic typing of consumed 
mushrooms was unavailable in our cases, and this is a well-
known problem in MP in all countries. The AAPCC reported 
an unknown mushroom type in 79.3% of cases in 2010.[12]
Patients who were transferred from other health care cen-
ters were a significant majority of our cases (79.8%). In our 
previous studies, we have found and published higher mor-
tality and complication rates in patients admitted to and 
cared for in another hospital for couple days before being 
transferred to our emergency department.[6-8] Unfortunately, 
we have no data on the previous treatments used in such 
cases, and we cannot perform a detailed discussion on the 
treatments of transferred patients that may affect outcome. 
However, transferred patients had higher ICU admissions, 
longer lengths of stay, and higher mortality and complica-
tion rates in our study, and these results suggest that they 
may not receive enough supportive treatment in previous 
facilities and/or delayed transfer8. Our mortality (3.7%) and 
complication (4.0%) rate is higher than some other reports.
[3,12] This might be due to medical treatment initiated rela-
tively late in previous health care centers. Yardan et al. re-
ported three deaths in their hospital (0.9%) in six years.[3]
In a regional poison center report,[4] 91.2% of cases were 
observed and had medical care in emergency departments. 
In our study, this percentage was 20.5%. They also reported 
that 3.3% of cases had ward and ICU admission, but this rate 
was 79.4% in our study. We transferred five cases (0.8%) to 
different hospitals that had facilities for liver transplantation. 
The transfer rate was reported as 5.4% in Hocaoglu’s report.
[4] We believe that this report reflects the regional fact more 
rationally. Regional and institutional differences for health 
care facilities affect patient care and outcomes in MP. Un-
fortunately, there is no current MP guideline in the English 
literature, so each institution and region must create its own 
specific approach to these cases.
Laboratory results (BUN, Cr, ALT, AST) were higher in fatal and 
complicated cases in our study. Trabulus et al. described the 
factors associated with greater likelihood of death[10] such 
as low sodium values and high urea, AST, ALT, total biliru-
bin, lactate dehydrogenase, prothrombin time, international 
normalized ratio (INR), and activated partial thromboplastin 
time values. Some laboratory (INR, etc.) and clinical (enceph-
alopathy, etc.) parameters have also been reported as fac-
tors associated with outcome of the patients who needed 
liver transplantation.[11]
Limitations
Our study has several limitations. This is a retrospective 
analysis of cases despite the organized prospective data 
compilation. Because there are no particular descriptions of 
mushroom type by patients or relatives, and we did not de-
termine the type of mushroom in our laboratory, this uncer-
tain information make some biases in admitted cases. When 
symptoms happened after consumption of mushrooms, 
foodborne illnesses caused by other ingredients of the meal 
could not be eliminated. We did not include treatment pa-
rameters into the study that may play an important role in 
outcomes. Because we have no data on previous treatment 
of transferred patients (the majority of our cases), we could 
not include these data in our analyses. We did not evalu-
ate the relationship of vital signs to outcome because we 
previously showed that vitals signs are not a parameter for 
outcome in MP.[7] Unfortunately, we could not process the 
data concerning symptom time after ingestion, which is a 
parameter related to outcome.[11] Finally, we could not use 
16% of the data, which may affect the results. We also ap-
plied logistic regression analysis for age, presenting season, 
the means of obtaining mushrooms, and presenting symp-
toms. However, the group of variables that we chose here 
were not able to predict mortality and complication rate in 
high percentage of patients. The retrospective data collec-
tion and institution specific decisions on admissions and 
other critical factors related to patient management might 
have affected these results. Prospective data collection and 
choosing the variables after correlation with outcome mea-
sures will give a more accurate analysis on logistic regres-
sion.
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Conclusion
We retrospectively analyzed demographic and clinical fac-
tors to evaluate their importance on outcome. Some factors, 
such as being elderly, summer season, purchased WM, and 
gastrointestinal symptoms, were significantly associated 
with mortality and complications in our study. Since our 
study showed that elderly patients have the highest mortal-
ity and complication rates, we suggest that emergency phy-
sicians and ICU physicians should pay special attention in 
taking care of this age group. Local or national laws should 
ban selling of WMs in public markets. Emergency physicians 
may also play a more active role in educating the public on 
MP. Since the mortality and complication rates of patients 
who directly presented to our tertiary care center was low-
er, we may suggest that MP cases should be transferred as 
soon as possible to experienced centers in high-risk regions. 
These variables and outcome measures should be evaluated 
and analyzed with logistic regression in prospective studies.
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